Divis Laboratories Share News - Latest Updates, Live News & More

Latest news about Divis Laboratories

Divi's Laboratories Clears US FDA Inspection with Zero Observations Nov 17, 2025

Divi's Laboratories' Unit-I facility successfully completed a US FDA inspection from November 10 to November 14, receiving zero 483 observations. This outcome indicates full regulatory compliance, ensuring continued access to the US market and reflecting positively on the company's quality control measures and manufacturing practices.

Divis Laboratories Reports 17% Revenue Growth in Q2 FY2026, Custom Synthesis Drives Performance Nov 13, 2025

Divis Laboratories Faces Significant Export Decline Nov 11, 2025

Divi's Labs Q2 Performance Surpasses Expectations with 17% Revenue Growth Nov 10, 2025

Divi's Laboratories Reports Strong Q2 FY26 Results with 17% Revenue Growth Nov 07, 2025

More news about Divis Laboratories

20Oct 25

Divi's Lab Stock May Face Pressure Amid Trump's Proposed Drug Price Cuts

Former U.S. President Donald Trump's pledge to reduce Ozempic's price by 90% if re-elected could impact Divis Laboratories. While Divis doesn't manufacture Ozempic, the proposal might affect investor sentiment towards pharmaceutical stocks, increase scrutiny on drug pricing, and potentially impact profit margins in the pharmaceutical supply chain. The current price of Ozempic in the U.S. is $1300, compared to $130 in London, highlighting the significant price disparity.

10Sept 25

Divi's Laboratories Sees Rs. 51.91 Crore Block Trade on NSE

Divi's Laboratories experienced a significant block trade on the National Stock Exchange (NSE). The transaction involved 87,739 shares at Rs. 5,916.50 per share, totaling Rs. 51.91 crore. This block trade highlights institutional interest in the pharmaceutical company, known for its production of active pharmaceutical ingredients and intermediates.

05Sept 25

Divi's Laboratories Announces Retirement of General Manager Y.S. Koteswara Rao

Divis Laboratories Limited has announced that Y.S. Koteswara Rao, General Manager of Personnel and Administration (P&A), will retire effective September 5, 2025. Mr. Rao will cease to be a Senior Management Personnel at the close of business hours on that date. The company disclosed this information in compliance with SEBI regulations. No information about a successor or transition plan has been provided yet.

12Aug 25

Divi's Laboratories Reports 15% Revenue Growth in Q1, Driven by Custom Synthesis Expansion

Divi's Laboratories reported a 15% year-over-year increase in consolidated revenue to ₹2,529.00 crores for Q1 ended June 30. Profit after tax grew 27% to ₹545.00 crores. The company maintained a balanced product mix with generics at 47% and custom synthesis at 53% of revenue. Exports accounted for 88% of total revenue, with Europe being the largest market at 58%. The new Unit 3 facility in Kakinada commenced production in January. The company expects ₹2,000.00 crores in capital expenditure for the current financial year. The nutraceutical segment showed 40% year-over-year growth, reaching ₹250.00 crores in revenue.

06Aug 25

Divi's Laboratories Reports Mixed Q1 Results with Revenue Growth but Missed Estimates

Divis Laboratories reported Q1 revenue of ₹2,410.00 crore, up 14% year-on-year, but slightly below estimates. Net profit increased 27% to ₹545.00 crore, missing projections. EBITDA rose 16.3% to ₹756.00 crore with a margin of 31.4%. The stock declined 3.3% following the announcement. Key focus areas include MSN's patent litigation win, long-term supply agreements, and GLP-1 opportunities.

10Jul 25

Divi's Laboratories Sees Robust Export Growth in June and Q1

Divi's Laboratories has shown significant export growth. In June, exports reached USD 98.50 million, a 38% year-over-year increase. For Q1, exports totaled USD 238.00 million, marking a 12% growth compared to the previous year. This performance indicates sustained demand for the company's products in international markets.

24May 25

Divi's Labs Secures Major Supply Agreement with Global Pharma Giant

Divi's Laboratories has entered into a long-term manufacturing and supply agreement with a global pharmaceutical company for advanced intermediates. The deal, valued between ₹650-750 crore, is expected to boost revenue, enhance global presence, provide long-term stability, and potentially advance technological capabilities. This agreement underscores India's growing importance in the global pharmaceutical supply chain.

19May 25

Divi's Labs Projects Double-Digit Growth, Stock Rises on Strong Q4 Results

Divi's Laboratories reported strong Q4 results, exceeding estimates and causing shares to rise up to 4%. The company expects double-digit growth in FY26, driven by operational improvements including the commencement of Unit III. Divi's is exploring new opportunities in GLP-1s and peptides while maintaining a conservative approach to projections. Despite positive results, brokerage views remain mixed with price targets ranging from ₹5,800 to ₹7,225.

17May 25

Divis Laboratories Q4 Results: EBITDA Surges 21%, Net Profit Jumps 23%

Divis Laboratories has announced impressive Q4 financial results. Revenue increased by 12.20% to ₹2,585.00 crore, EBITDA rose by 21.20% to ₹886.00 crore, and net profit climbed by 23.00% to ₹662.00 crore compared to the previous year. The EBITDA margin improved to 34.27% from 31.74%. Quarter-on-quarter growth was also notable, with revenue up 7.66%, EBITDA up 7.39%, and net profit up 12.39% compared to Q3.

02May 25

Divi's Laboratories Sees Significant Block Trade on NSE

A significant block trade of approximately 100,045 shares of Divi's Laboratories Ltd. occurred on the National Stock Exchange (NSE), valued at Rs. 60.77 crores. The trade was executed at Rs. 6,074.50 per share, reflecting current market valuations for the pharmaceutical company. This large transaction is likely to impact the day's trading volume and may attract attention from market participants.

02May 25

Divi's Laboratories Sees Significant Block Trade on NSE

A significant block trade of 144,937 shares of Divi's Laboratories Ltd. occurred on the National Stock Exchange (NSE) at Rs. 6,114.00 per share, totaling Rs. 88.61 crores. This large transaction could potentially indicate a shift in institutional holdings or a strategic move by a major investor. Divi's Laboratories, known for manufacturing active pharmaceutical ingredients and intermediates, is a key player in the Indian pharmaceutical sector.

21Apr 25

Divi's Laboratories Inks Long-term Manufacturing Deal and Unveils Expansion Plans

Divi's Laboratories has entered a long-term manufacturing agreement with a global pharmaceutical company for advanced intermediates. Additionally, the company plans to invest Rs 650-700 crore in a capacity expansion project, funded entirely through internal resources. These moves aim to strengthen Divi's market position and manufacturing capabilities in the pharmaceutical industry.

19Apr 25

Divi's Laboratories Secures Long-Term Manufacturing Deal and Announces Expansion Plans

Divi's Laboratories has entered into a long-term manufacturing agreement with a global pharmaceutical company for advanced intermediates. Additionally, the company plans to invest Rs 650-700 crore in a capacity expansion project, to be funded internally. These moves aim to strengthen Divi's market position and manufacturing capabilities in the pharmaceutical sector.

18Apr 25

Divi's Laboratories Inks Major Supply Deal, Plans Rs 700 Crore Investment

Divi's Laboratories has secured a long-term supply agreement with a global pharmaceutical company for advanced intermediates. The company expects significant revenue contributions from this deal in the coming years. To support this and future growth, Divi's plans to invest Rs 650-700 crore in capacity expansion, funded entirely through internal accruals.

11Apr 25

Divis Laboratories Reports 22% Growth in Exports, Reaching $85 Million

Divis Laboratories, a leading Indian CDMO, has reported significant export growth. Annual exports reached $85.00 million, a 22% year-over-year increase. The fourth quarter saw a 23% surge compared to the previous year. This growth underscores Divis' expanding role in the global pharmaceutical supply chain and suggests increasing demand for its services internationally.

21Feb 25

Divi's Laboratories Sees Significant Block Trade on NSE

A significant block trade of 203,922 shares of Divi's Laboratories Ltd. occurred on the National Stock Exchange at Rs. 5,790.00 per share, totaling Rs. 118.07 crores. The transaction, likely involving institutional investors, has drawn market attention due to its scale. While the parties involved remain undisclosed, such trades can potentially influence stock prices and indicate shifts in institutional holdings.

Divis Laboratories

6,417.50

-5.00

(-0.08%)

1 Year Returns:+2.59%

Industry Peers